leukemia

Micromet shares traded some 3.3% higher on Monday after the small-cap biotech announced that its candidate drug blinatumomab led to remission in almost four-fifths of leukemia patients in a Phase II trial. It also said that a Phase I trial showed the drug induced durable remission in patients with non-Hodgkin lymphoma.

There must be holiday cheer in the executive suite at biotech Celgene (CELG), where the stock is up 15% over last year. The Summit, N.J.-based company's cancer pill Revlimid generated $1.3 billion in sales last year. And it did so as a backup therapy for patients with the blood cancer multiple...